Reversible posterior leukoencephalopathy syndrome associated with carbamazepine-induced hypertension

Furuta, Natsumi; Fujita, Yukio; Sekine, Akiko; Ikeda, Masaki; Okamoto, Koichi

doi:10.5692/clinicalneurol.49.191

Cited by 9 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Literature search was conducted which showed six reports on carabamazepine-induced hypertension from various countries. [ 9 10 11 12 13 14 ] All the cases had patients who developed hypertension during carbamazepine treatment which resolved on discontinuation. To the best of our knowledge, this is the first report of carbamazepine-induced hypertension from India.…”

Section: Discussionmentioning

confidence: 99%

Carbamazepine-induced hypertension: A rare case

Kharb

Mittal

Gupta

2015

Journal of Pharmacology and Pharmacotherapeutics

View full text Add to dashboard Cite

A 74-year-old female with trigeminal neuralgia developed hypertension after the initiation of carbamazepine therapy. The time sequence of start of the suspected drug and onset of hypertension are consistent with the diagnosis. The hypertension did not resolve with antihypertensive therapy or dose reduction of carbamazepine. Patient recovered after the carbamazepine therapy was discontinued. The positive rechallenge and positive dechallenge showed association of carbamazepine therapy with hypertension as its adverse effect. This is a rare case that we report of carbamazepine-induced hypertension and this report may act as alerting mechanism to the health care professionals especially neurologists.

show abstract

Section: Discussionmentioning

confidence: 99%

Carbamazepine-induced hypertension: A rare case

Kharb

Mittal

Gupta

2015

Journal of Pharmacology and Pharmacotherapeutics

View full text Add to dashboard Cite

show abstract

“…1 To the best of our knowledge, this is the second case report showing PRES associated with carbamazepine administration. Furuta et al 3 were the first to report the development of PRES induced by carbamazepine, which was in a 21-year-old male. Because carbamazepine is commonly administered in various neurological disorders such as epilepsy, trigeminal neuralgia, and neuromyelitis optica spectrum disorder related tonic spasms, neurologists should be aware that this drug can induce PRES, even when it is administered within the therapeutic range.…”

Section: Posterior Reversible Encephalopathy Syndrome Related To Carbmentioning

confidence: 99%

Posterior Reversible Encephalopathy Syndrome Related to Carbamazepine-Induced Hypertension

2020

View full text Add to dashboard Cite

“…Bevacizumab [20] Sunitinib [21] Raf kinase inhibiteur BAY 43-9006 [22] Cytokines immunomodulatrices Interféron alpha [5,23] Interleukine 2 [24] Anticorps Monoclonaux Rituximab (anti-CD20) [25] Infliximab (anti-TNFα) [26] Immunoglobulines intraveineuses [27] Protéine Anti-TNFα Étanercept [28] Globuline antilymphocyte [29] Immunosuppresseurs Anticalcineurine [8] Cyclosporine A [4,5,7,10,12] Tacrolimus (FK 506) [5,10,12] Sirolimus [30] Corticothérapie forte dose (dexaméthasone et méthylprednisolone) Transfusion sanguine [31] Autres agents Facteurs de croissance leurocytaires [32] Antirétroviraux [33] Linezolid [34] Érythropoïétine [35] Cocaïne [10] Ephedra sinica (médecine traditionnelle chinoise) [36] Produits de contraste intraveineux [10] Lysergic acid amide [37] Carbamazépine [38] Caféine intraveineuse [39] Maladies auto-immunes…”

Section: Prééclampsie-éclampsieunclassified